Loroblis®
54,43 lei
Compozitie
Un comprimat orodispersabil Loroblis® contine ( minimum ) 1×109 UFC Streptococcus salivarius K12 (BLIS K12).
Streptococcus salivarius K12 este o tulpina bacteriana care colonizeaza cavitatea bucala si nazofaringele indivizilor sanatosi si face parte din flora bacteriana normala.
Mecanism de actiune
Desi este o tulpina bacteriana comensala, Streptococcus salivarius K12 produce 2 bacteriocine: peptidele antimicrobiene Salivaricin A2 si Salivaricin B care au potentialul de a inhiba dezvoltarea tulpinilor bacteriene patogene, responsabile pentru faringite si amigdalite bacteriene, otite medii acute si halitoza (de exemplu, Streptococcus pyogenes, Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis).
Pe langa potentialul de a mentine si de a restabili eubioza la nivelul cavitatii bucale si a faringelui, Streptococcus salivarius K12 are activitate antivirala, activitate anti-inflamatorie si proprietati antimicotice, sustinute de studii in vitro si in vivo.
Recomandare
Studiile clinice au aratat ca Loroblis® contribuie la mentinerea si dezvoltarea unei flore microbiene cu rol protectiv la nivelul cavitatii orale si faringelui, cu potential in:
– Profilaxia infectiilor tractului respirator superior (faringite, amigdalite, otite medii);
– Terapia infectiilor usoare si medii ale tractului respirator superior;
– Terapia afectiunilor inflamatorii orale (stomatite, gingivite, candidoza, halitoza);
– Terapia de sustinere dupa tratamentul antibiotic al infectiilor tractului respirator superior.
Mod de administrare
Loroblis® se recomanda adultilor si copiilor mai mari de 3 ani: 1 comprimat orodispersabil/ zi, dizolvat lent in cavitatea orala, seara dupa igiena orala, in functie de recomandarea medicului dumneavoastra, pana la 1 comprimat orodispersabil/zi, timp de 90 de zile pentru profilaxia infectiilor recurente ale tractului respirator superior (faringite, amigdalite, otite medii recurente).
Este inutila administrarea Loroblis® concomitent cu antibioticul, datorita sensibilitatii puternice la antibiotice a tulpinii Streptococcus salivarius K12;
Persoanele imunodeprimate, care urmeaza anumite tratamente (chimioterapie, radioterapie) ori au leucopenie severa sa consulte medicul inainte de administrarea produsului.
Trebuie să fii autentificat pentru a publica o recenzie.
Loroblis®
54,43 lei
Composition
One Loroblis® Oro dispersible tablet contains (minimum) 1 × 109 CFU Streptococcus salivarius K12 (BLIS K12).
Streptococcus salivarius K12 is a bacterial strain that colonizes the oral cavity and nasopharynx of healthy individuals and is part of the normal bacterial flora.
Mechanism of action
Although a common bacterial strain, Streptococcus salivarius K12 produces 2 bacteriocins: the antimicrobial peptides Salivaricin A2 and Salivaricin B, which have the potential to inhibit the development of pathogenic bacterial strains, responsible for bacterial pharyngitis and tonsillitis, acute otitis media and halitosis (e.g., Streptococcus pyogenes, Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis).
In addition to the potential to maintain and restore eubiosis in the oral cavity and pharynx, Streptococcus salivarius K12 has antiviral activity, anti-inflammatory activity and antifungal properties, supported by in vitro and in vivo studies.
Recommendation
Clinical studies have shown that Loroblis® contributes to the maintenance and development of a microbial flora with a protective role in the oral cavity and pharynx, with potential in:
– Prophylaxis of upper respiratory tract infections (pharyngitis, tonsillitis, otitis media);
– Therapy for mild and moderate upper respiratory tract infections;
– Therapy of oral inflammatory diseases (stomatitis, gingivitis, candidiasis, halitosis);
– Supportive therapy after antibiotic treatment of upper respiratory tract infections.
Administration method
Loroblis® is recommended for adults and children older than 3 years: 1 Oro dispersible tablet / day, slowly dissolved in the oral cavity, evening after oral hygiene, depending on your doctor’s recommendation, up to 1 Oro dispersible tablet / day for 90 days for the prophylaxis of recurrent infections of the upper respiratory tract (pharyngitis, tonsillitis, recurrent otitis media).
Co-administration of Loroblis® with antibiotics is unnecessary due to the strong antibiotic sensitivity of Streptococcus salivarius K12;
Immunocompromised individuals undergoing certain treatments (chemotherapy, radiation therapy) or severe leukopenia should consult a physician prior to administration of the product.
opinii
Trebuie să fii autentificat pentru a publica o recenzie.
opinii